Your TB Evaluation Matters
One-third of the world’s population is affected by TB. If exposed to infectious TB, anyone can get infected and progress to disease. Most TB disease is diagnosed in private medical settings with city/county public health departments providing case management support and contact investigations to identify related TB infections and disease. Private providers, working with public health personnel provide prevent large and ongoing outbreaks of TB.
The CDC is offering the following web-based CME course, Interactive Core Curriculum on Tuberculosis: What the Clinician Should Know – Continuing Education Activities.
On September 6, 2016, the Recommendation: Screening for Latent Tuberculosis Infection in Adults was published here JAMA. 2016;316(9):962-969.
Image Source: World Health Organization; Image credit: Rebeccah Robinson
Who to test:
Avoid testing persons at low risk
Routine testing of
Prioritize persons with risks for progression
If health system resources do not allow for testing of all foreign-born persons from a country with an elevated TB rate, prioritize patients with at least one of the following medical risks for progression: diabetes mellitus, smoker within past 1 year,
If LTBI Test is Positive and TB Disease is ruled out, LTBI Treatment may be recommended.
Consult with your public health department TB Control Program, and see Calfornia Department of Public Health TB Control Branch information about the 12 dose treatment
Additional Information and Resources:
A TB Symptoms Sheet is available to use in your office, clinic or community center. (Print “actual size.”)
A TB Self-Assessment Sheet is available to use in your office, clinic or community center.
(Print “actual size.”)
Additional guidance for the care and control of TB in California can be found through the following linked pages on this website:
CDPH-CTCA Joint Guidelines
CA TB Legal Resources
IGRA Fact Sheet
The California Department of Public Health (CDPH) in collaboration with CTCA and the Curry International Tuberculosis Center (CITC) created the following risk assessments to reduce low-risk testing and to find TB infection, in order to treat those likely to develop TB disease to prevent illness.
BCG, or Bacille Calmette-Guérin, is a vaccine for TB disease. Many persons born outside of the United States have been BCG-vaccinated. BCG vaccination may cause a positive reaction to the TB skin test, which may complicate decisions about prescribing treatment. Despite this potential for BCG to interfere with test results, the TB skin test is not contraindicated for persons who have been vaccinated with BCG. The presence or size of a TB skin test reaction in these persons does not predict whether BCG will provide any protection against TB disease. Furthermore, the size of a TB skin test reaction in a BCG-vaccinated person is not a factor in determining whether the reaction is caused by latent TB infection (LTBI) or the prior BCG vaccination.
TB blood tests (interferon-gamma release assays or IGRAs), unlike the TB skin tests, are not affected by prior BCG vaccination and are not expected to give a false-positive result in persons who have received prior BCG vaccination.
For more information on who to test for TB go